PIDD1

Summary

Gene Symbol: PIDD1
Description: p53-induced death domain protein 1
Alias: LRDD, PIDD, p53-induced death domain-containing protein 1, leucine-rich repeat and death domain-containing protein, leucine-rich repeats and death domain containing, p53-induced protein with a death domain
Species: human
Products:     PIDD1

Top Publications

  1. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 2000;26:122-7 pubmed
    ..by p53 that encodes a predicted protein of 915 amino acids in mice (910 amino acids in humans), which we have named Pidd. The mouse Pidd cDNA contains a p53 consensus DNA binding sequence upstream of the Pidd-coding region...
  2. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004;304:843-6 pubmed
    ..We show that activation of caspase-2 occurs in a complex that contains the death domain-containing protein PIDD, whose expression is induced by p53, and the adaptor protein RAIDD...
  3. Telliez J, Bean K, Lin L. LRDD, a novel leucine rich repeat and death domain containing protein. Biochim Biophys Acta. 2000;1478:280-8 pubmed
    ..In this paper we report the cloning of a new human gene called LRDD (leucine repeat death domain containing protein)...
  4. Park J, Kanayama A, Yamamoto K, Miyamoto Y. ARD1 binding to RIP1 mediates doxorubicin-induced NF-κB activation. Biochem Biophys Res Commun. 2012;422:291-7 pubmed publisher
    ..in DNA damage-induced NF-κB activation by forming a complex with the p53 interacting death domain protein (PIDD) and NF-κB essential modulator (NEMO) in the nucleus, although the underlying mechanism of this interaction has ..
  5. Mitchell R. Hematopoietic Stem Cell Transplantation Beyond Severe Combined Immunodeficiency: Seeking a Cure for Primary Immunodeficiency. J Allergy Clin Immunol Pract. 2019;7:776-785 pubmed publisher
    ..stem cell transplantation (HSCT) can provide definitive therapy for patients with primary immunodeficiency disease (PIDD). Modern HSCT techniques and supportive care have significantly improved outcomes for patients with PIDD...
  6. Němcová Fürstová V, James R, Kovar J. Inhibitory effect of unsaturated fatty acids on saturated fatty acid-induced apoptosis in human pancreatic β-cells: activation of caspases and ER stress induction. Cell Physiol Biochem. 2011;27:525-38 pubmed publisher
    ..Furthermore, stearic acid treatment was not associated with changes in p21(WAF1/CIP1), PIDD, Fas receptor and Fas ligand expression. However, we detected endoplasmic reticulum (ER) stress markers, i. e...
  7. Fahira A, Li Z, Liu N, Shi Y. Prediction of causal genes and gene expression analysis of attention-deficit hyperactivity disorder in the different brain region, a comprehensive integrative analysis of ADHD. Behav Brain Res. 2019;364:183-192 pubmed publisher
    ..Overall 47 genes were prioritized, the most promising genes were LSG1, HYAL3, PIDD, PNPLA2, BLOC1S2, PLK1S1, CALN1, KAT2B, CTNNB1 and WDR11...
  8. Naganna N, Opoku Temeng C, Choi E, Larocque E, Chang E, Carter Cooper B, et al. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice. EBioMedicine. 2019;40:231-239 pubmed publisher
    ..FUND: Purdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Research, Elks Foundation and NIH P30 CA023168.
  9. Liu P, Shah R, Li Y, Arora A, Ung P, Raman R, et al. An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nat Cell Biol. 2019;21:203-213 pubmed publisher
    ..nuclear factor-κB, radiation-activated IRAK1 prevented apoptosis mediated by the PIDDosome complex (comprising PIDD, RAIDD and caspase-2)...

More Information

Publications83

  1. Harris K, Davila B, Bollard C, Keller M. Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2019;7:809-818 pubmed publisher
    ..viral susceptibility stems from poor to absent T-cell function in most patients with moderate to severe forms of PIDD, adoptive immunotherapy with virus-specific T cells (VSTs) has been used to combat viral infections in the setting ..
  2. Mallick R, Jolles S, Kanegane H, Agbor Tarh D, Rojavin M. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies. J Clin Immunol. 2018;38:886-897 pubmed publisher
    ..Most patients with PIDD require life-long immunoglobulin G replacement therapy, which has been shown to reduce the rate of infections and, ..
  3. Squire J, Gardner P, Moutsopoulos N, Leiding J. Antibiotic Prophylaxis for Dental Treatment in Patients with Immunodeficiency. J Allergy Clin Immunol Pract. 2019;7:819-823 pubmed publisher
    ..We review risk factors and provide recommendations on routine dental care and antibacterial prophylaxis in patients with primary immunodeficiency diseases. ..
  4. Shamriz O, Chandrakasan S. Update on Advances in Hematopoietic Cell Transplantation for Primary Immunodeficiency Disorders. Immunol Allergy Clin North Am. 2019;39:113-128 pubmed publisher
    ..HSCT should be tailored to the underlying PIDD, as different PIDDs, such as severe combined immune deficiency, Treg dysfunction, and phagocytic disorders, have ..
  5. Rolfes M, Sriaroon P, Dávila Saldaña B, Dvorak C, Chapdelaine H, Ferdman R, et al. Chronic norovirus infection in primary immune deficiency disorders: an international case series. Diagn Microbiol Infect Dis. 2019;93:69-73 pubmed publisher
    ..associated with clinical outcomes of chronic norovirus infection (CNI) in primary immunodeficiency diseases (PIDD) are lacking...
  6. Wang Y, Liu C, Wang J, Zhang Y, Chen L. Iodine-131 induces apoptosis in human cardiac muscle cells through the p53/Bax/caspase-3 and PIDD/caspase-2/ t‑BID/cytochrome c/caspase-3 signaling pathway. Oncol Rep. 2017;38:1579-1586 pubmed publisher
    ..We found that iodine-131 reduced cell proliferation, induced apoptosis, induced p53, PIDD, t-BID (mitochondria) protein expression, suppressed cytochrome c (mitochondria) protein expression, and ..
  7. Younger E, Epland K, Zampelli A, Hintermeyer M. Primary immunodeficiency diseases: a primer for PCPs. Nurse Pract. 2015;40:1-7 pubmed publisher
    ..This diagnosis has implications for PCPs, as patients continue to require primary care and management after a PIDD diagnosis has been made. This review presents essential information for PCPs regarding PIDDs.
  8. Kung C, Khaku S, Jennis M, Zhou Y, Murphy M. Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes. Mol Cancer Res. 2015;13:250-62 pubmed publisher
    ..of p53 to transactivate a subset of proapoptotic target genes associated with prolonged oxidative stress, including PIDD, PIG3 (TP53I3), and PIG6 (PRODH)...
  9. Leung J, Sullivan K, Perelygina L, Icenogle J, Fuleihan R, Lanzieri T. Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States: Data From National Health Care Claims and the US Immunodeficiency Network Registry. J Clin Immunol. 2018;38:717-726 pubmed publisher
    ..a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD...
  10. Hernandez Trujillo V, Scalchunes C, Hernandez Trujillo H, Boyle J, Williams P, Boyle M, et al. Primary Immunodeficiency Diseases: An Opportunity in Pediatrics for Improving Patient Outcomes. Clin Pediatr (Phila). 2015;54:1265-75 pubmed publisher
    ..The objective of this study was to evaluate understanding, recognition, and diagnosis of PIDD among pediatricians...
  11. Chinen J, Cowan M. Advances and highlights in primary immunodeficiencies in 2017. J Allergy Clin Immunol. 2018;142:1041-1051 pubmed publisher
    ..The remarkable progress in the understanding and management of PIDDs reflects the current interest in this area and continues to improve the care of immunodeficient patients. ..
  12. Buchbinder D, Baker R, Lee Y, Ravell J, Zhang Y, McElwee J, et al. Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders. J Clin Immunol. 2015;35:119-24 pubmed publisher
    ..one patient and the use of a gene panel designed to target genes known to cause primary immunodeficiency disorders (PIDD) in a second patient. Sanger dideoxy sequencing was used to confirm RAG1 mutations in both patients...
  13. Nematollahi L, Garza Garcia A, Bechara C, Esposito D, Morgner N, Robinson C, et al. Flexible stoichiometry and asymmetry of the PIDDosome core complex by heteronuclear NMR spectroscopy and mass spectrometry. J Mol Biol. 2015;427:737-752 pubmed publisher
    ..The structure of the PIDDosome core complex exhibits an asymmetric three-layered arrangement containing five PIDD-DDs in one layer, five RAIDD-DDs in a second layer and an additional two RAIDD-DDs...
  14. Dong X, Tong F, Qian C, Zhang R, Dong J, Wu G, et al. NEMO modulates radiation-induced endothelial senescence of human umbilical veins through NF-κB signal pathway. Radiat Res. 2015;183:82-93 pubmed publisher
    ..with PS1145 inhibited the increase of mRNA expressions of interleukin-6 (IL-6) and p53-induced death domain (PIDD) protein, which have been show to play crucial roles in both senescence and apoptosis (P < 0.05)...
  15. Kang D, Jadin L, Nekoroski T, Drake F, Zepeda M. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model. Drug Deliv Transl Res. 2012;2:254-64 pubmed publisher
    Many patients with primary immunodeficiency disease (PIDD) require lifelong immunoglobulin (Ig) replacement therapy...
  16. Jang T, Lim I, Kim C, Choi J, Kim E, Lee T, et al. Rescuing neuronal cell death by RAIDD- and PIDD- derived peptides and its implications for therapeutic intervention in neurodegenerative diseases. Sci Rep. 2016;6:31198 pubmed publisher
    ..Our newly designed TAT-fused peptides, which contains wild-type helix number3 (H3) from RAIDD and PIDD, blocked the PIDDosome formation in vitro...
  17. Hartono S, Ippoliti M, Mastroianni M, Torres R, Rider N. Gastrointestinal Disorders Associated with Primary Immunodeficiency Diseases. Clin Rev Allergy Immunol. 2018;: pubmed publisher
    ..96-128, 2018]. Often, the gastrointestinal symptomatology and pathology is the heralding sign of a PIDD; therefore, it is important to recognize patterns of disease which may manifest along the gastrointestinal tract as ..
  18. Seagle B, Yang C, Eng K, Dandapani M, Odunsi Akanji O, Goldberg G, et al. TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecol Oncol. 2015;138:159-64 pubmed publisher
    ..Expression of p53 target genes P21, GADD45, BAX, PIDD, NF-kB2, PAI-1, and MDR1 was measured by RT-PCR. cBioPortal...
  19. Dong X, Luo M, Huang G, Zhang J, Tong F, Cheng Y, et al. Relationship between irradiation-induced neuro-inflammatory environments and impaired cognitive function in the developing brain of mice. Int J Radiat Biol. 2015;91:224-39 pubmed publisher
    ..of IkappaB-alpha (IκB-α), NF-κB essential modulator (NEMO), p53-induced protein with a death domain (PIDD), TNF-α and IL-1β were examined by Western blotting...
  20. Sokolic R. Neutropenia in primary immunodeficiency. Curr Opin Hematol. 2013;20:55-65 pubmed publisher
    ..Granulocyte-colony stimulating factor is the treatment of choice for neutropenia in PIDD, whereas hematopoietic cell transplantation is the only curative option...
  21. Klinck R, Laberge G, Bisson M, McManus S, Michou L, Brown J, et al. Alternative splicing in osteoclasts and Paget's disease of bone. BMC Med Genet. 2014;15:98 pubmed publisher
    ..The corresponding genes included LGALS8, RHOT1, CASC4, USP4, TBC1D25, and PIDD. In addition, RHOT1 and LGALS8 genes were upregulated in pagetic OCs, as were CASC4 and RHOT1 genes in the presence ..
  22. Ray P, Guha D, Chakraborty J, Banerjee S, Adhikary A, Chakraborty S, et al. Crocetin exploits p53-induced death domain (PIDD) and FAS-associated death domain (FADD) proteins to induce apoptosis in colorectal cancer. Sci Rep. 2016;6:32979 pubmed publisher
    ..cancer cells, p53 in one hand transactivates BAX and in parallel up-regulates p53-induced death domain protein (PIDD) that in turn cleaves and activates BID through caspase-2...
  23. Yu H, Zhang V, Stray Pedersen A, Hanson I, Forbes L, de la Morena M, et al. Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. J Allergy Clin Immunol. 2016;138:1142-1151.e2 pubmed publisher
    ..circle numbers on newborn screening or a positive family history or clinical suspicion of SCID or other severe PIDD identified deleterious mutations in 14 of them...
  24. Yang N, Gao X, Qu X, Zhang R, Tong F, Cai Q, et al. PIDD Mediates Radiation-Induced Microglia Activation. Radiat Res. 2016;186:345-359 pubmed
    ..In this study we examined the role of p53-induced protein with a death domain (PIDD) in radiation-induced activation of BV-2 cells...
  25. Patel N, Gallagher J, Ochs H, Prescott Atkinson T, Wahlstrom J, Dorsey M, et al. Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age. J Clin Immunol. 2015;35:558-65 pubmed publisher
    ..administration in adults and children 2 years of age and older who have primary immunodeficiency disease (PIDD)...
  26. ROUTES J, Costa Carvalho B, Grimbacher B, Paris K, Ochs H, Filipovich A, et al. Health-Related Quality of Life and Health Resource Utilization in Patients with Primary Immunodeficiency Disease Prior to and Following 12 Months of Immunoglobulin G Treatment. J Clin Immunol. 2016;36:450-61 pubmed publisher
    ..health resource utilization (HRU) were assessed in newly diagnosed patients with primary immunodeficiency disease (PIDD) pre- and 12 months post-IgG treatment initiation...
  27. Okuda A, Kurokawa S, Takehashi M, Maeda A, Fukuda K, Kubo Y, et al. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells. BMC Neurosci. 2017;18:14 pubmed publisher
    ..in the p53 signaling pathway were upregulated, including Cdkn1a, which is critical for cell cycle control, and Fas, Pidd, Pmaip1, and Bbc3, which are principal factors in the apoptosis pathway...
  28. Kobrynski L, Powell R, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J Clin Immunol. 2014;34:954-61 pubmed publisher
    Few studies have estimated population prevalence and morbidity of primary immunodeficiency diseases (PIDD). We used administrative healthcare databases to estimate the prevalence of PIDD diagnoses in the United States from 2001 to 2007...
  29. Kannappan R, Mattapally S, Wagle P, Zhang J. Transactivation domain of p53 regulates DNA repair and integrity in human iPS cells. Am J Physiol Heart Circ Physiol. 2018;315:H512-H521 pubmed publisher
    ..Therefore, activating p53-TAD domain using small molecules may promote DNA repair and integrity of cells and prevent cellular senescence. ..
  30. Rodrigues P, Afonso M, Simão A, Borralho P, Rodrigues C, Castro R. Inhibition of NF-κB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocellular apoptosis. Sci Rep. 2015;5:17528 pubmed publisher
    ..In turn, DCA-induced oxidative stress resulted in caspase-2 activation and NF-κB/miR-21 inhibition, in a PIDD-dependent manner...
  31. Stray Pedersen A, Sorte H, Samarakoon P, Gambin T, Chinn I, Coban Akdemir Z, et al. Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. J Allergy Clin Immunol. 2017;139:232-245 pubmed publisher
    ..Analytic approaches initially focused on 475 known or candidate PIDD genes but were nonexclusive and further tailored based on clinical data, family history, and immunophenotyping...
  32. Zhang Y, Yuan Y, Liang P, Zhang Z, Guo X, Xia L, et al. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer. Oncotarget. 2017;8:45459-45469 pubmed publisher
    ..In addition, upregulated expression of GADD45A, GADD45B, p21, PIDD and Shisa5, which contribute to growth arrest and apoptosis induction, and downregulated CCNB1 that promotes cell ..
  33. Samarakoon P, Sorte H, Stray Pedersen A, Rødningen O, Rognes T, Lyle R. cnvScan: a CNV screening and annotation tool to improve the clinical utility of computational CNV prediction from exome sequencing data. BMC Genomics. 2016;17:51 pubmed publisher
    ..cnvScan on CNV predictions from five different prediction programs using 64 exomes from Primary Immunodeficiency (PIDD) patients, and identified PIDD-causing CNVs in three individuals from two different families...
  34. Rider N, Kutac C, Hajjar J, Scalchunes C, Seeborg F, Boyle M, et al. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment. J Clin Immunol. 2017;37:461-475 pubmed publisher
    Common variable immunodeficiency disorder (CVID) is a primary immunodeficiency disease (PIDD) often associated with severe and chronic infections...
  35. Liu X, Zhang L, Zhang Z, Ma X, Liu J. Transcriptional response to sulfide in the Echiuran Worm Urechis unicinctus by digital gene expression analysis. BMC Genomics. 2015;16:829 pubmed publisher
    ..members, this is the first report on their association with sulfide stress, among which glycolysis pathway and PIDD involving pathways were unique and discussed in details, and were thought to play important roles in the sulfide ..
  36. Van Ginkel P, Yan M, Bhattacharya S, Polans A, Kenealey J. Natural products induce a G protein-mediated calcium pathway activating p53 in cancer cells. Toxicol Appl Pharmacol. 2015;288:453-62 pubmed publisher
    ..calcium modulates p53 activity and the subsequent transcription of several pro-apoptotic genes encoding PIG8, CD95, PIDD, TP53INP, RRM2B, Noxa, p21 and PUMA...
  37. Di Donato N, Jean Y, Maga A, Krewson B, Shupp A, Avrutsky M, et al. Mutations in CRADD Result in Reduced Caspase-2-Mediated Neuronal Apoptosis and Cause Megalencephaly with a Rare Lissencephaly Variant. Am J Hum Genet. 2016;99:1117-1129 pubmed publisher
    ..CRADD (also known as RAIDD) is a death-domain-containing adaptor protein that oligomerizes with PIDD and caspase-2 to initiate apoptosis...
  38. Zhang J, Tong F, Cai Q, Chen L, Dong J, Wu G, et al. Shenqi fuzheng injection attenuates irradiation-induced brain injury in mice via inhibition of the NF-κB signaling pathway and microglial activation. Acta Pharmacol Sin. 2015;36:1288-99 pubmed publisher
    ..number of activated microglia, expression levels of TNF-α and IL-1β, and the levels of phosphorylated p65 and PIDD-CC (the twice-cleaved fragment of p53-induced protein with a death domain) in the brain tissues...
  39. Rubin Z, Pappalardo A, Schwartz A, Antoon J. Prevalence and Outcomes of Primary Immunodeficiency in Hospitalized Children in the United States. J Allergy Clin Immunol Pract. 2018;6:1705-1710.e1 pubmed publisher
    ..The objectives of this study were to (1) determine the epidemiology of children hospitalized with PIDD in the United States and (2) characterize the clinical outcomes of hospitalized children with PIDDs...
  40. Ma C, Chen M, Lam J, Cheung K. A novel body frame based approach to aerospacecraft attitude tracking. ISA Trans. 2017;70:228-237 pubmed publisher
    ..on a quadrotor platform with unknown system parameters and disturbances, using a boundary layer approximated sliding mode controller, a PIDD controller, and a unit sliding mode controller. Significant tracking quality is attained.
  41. Sorte H, Osnes L, Fevang B, Aukrust P, Erichsen H, Backe P, et al. A potential founder variant in CARMIL2/RLTPR in three Norwegian families with warts, molluscum contagiosum, and T-cell dysfunction. Mol Genet Genomic Med. 2016;4:604-616 pubmed
    ..and/or persistent, and presenting together with other immunological features, a primary immunodeficiency disease (PIDD) may be suspected...
  42. Wasserman R, Lumry W, Harris J, Levy R, Stein M, Forbes L, et al. Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease. J Clin Immunol. 2016;36:590-9 pubmed publisher
    ..An IVIG was developed that satisfies the requirements for treating patients with primary immune deficiency disease (PIDD) and also has standardized elevated levels of RSV neutralizing antibodies (RI-002)...
  43. Wasserman R, Greener B, Mond J. RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations. Expert Rev Clin Immunol. 2017;13:1107-1119 pubmed publisher
    ..including Phase II and compassionate use studies of RI-001 and a multi-center, pivotal Phase III study of RI-002 in PIDD patients...
  44. Logette E, Schuepbach Mallepell S, Eckert M, Leo X, Jaccard B, Manzl C, et al. PIDD orchestrates translesion DNA synthesis in response to UV irradiation. Cell Death Differ. 2011;18:1036-45 pubmed publisher
    b>PIDD has been implicated in survival and apoptotic pathways in response to DNA damage, and a role for PIDD was recently identified in non-homologous end-joining (NHEJ) repair induced by ?-irradiation...
  45. Wang L, Yang J, Kabaleeswaran V, Rice A, Cruz A, Park A, et al. The Fas-FADD death domain complex structure reveals the basis of DISC assembly and disease mutations. Nat Struct Mol Biol. 2010;17:1324-9 pubmed publisher
    ..The structure optimally positions the FADD death effector domain (DED) to interact with the caspase-8 DED for caspase recruitment and higher-order aggregation. ..
  46. Shi W, Huang W, Chen Y, Zhang S, Xu P, Gu X, et al. Low expression of PIDD is associated with cell proliferation and apoptosis in hepatocellular carcinoma. Tumour Biol. 2016;37:10447-57 pubmed publisher
    p53-induced death domain protein (PIDD) facilitates p53-dependent apoptosis through the interaction with components of the death receptor signaling pathways...
  47. Suez D, Stein M, Gupta S, Hussain I, Melamed I, Paris K, et al. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America. J Clin Immunol. 2016;36:700-12 pubmed publisher
    Patients with primary immunodeficiency disease (PIDD) typically require life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy to prevent recurrent infections...
  48. Sullivan K, Bassiri H, Bousfiha A, Costa Carvalho B, Freeman A, Hagin D, et al. Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies. J Clin Immunol. 2017;37:650-692 pubmed publisher
    ..This is never more important than for patients with primary immunodeficiency disorders (PIDD)...
  49. Tinel A, Janssens S, Lippens S, Cuenin S, Logette E, Jaccard B, et al. Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and pro-survival NF-kappaB pathway. EMBO J. 2007;26:197-208 pubmed
    ..b>PIDD (p53-induced protein with a death domain) is constitutively processed giving rise to a 48-kDa N-terminal fragment ..
  50. Harel T, Hacohen N, Shaag A, Gomori M, Singer A, Elpeleg O, et al. Homozygous null variant in CRADD, encoding an adaptor protein that mediates apoptosis, is associated with lissencephaly. Am J Med Genet A. 2017;173:2539-2544 pubmed publisher
    ..fetus, revealed a homozygous frameshift variant in CRADD, which encodes an adaptor protein that interacts with PIDD and caspase-2 to initiate apoptosis...
  51. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell. 2005;123:1079-92 pubmed
    ..Previously, we reported a role for the p53-inducible death-domain-containing protein, PIDD, in caspase-2 activation and apoptosis in response to DNA damage...
  52. Bradley G, Tremblay S, Irish J, MacMillan C, Baker G, Gullane P, et al. The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma. Br J Cancer. 2007;96:1425-32 pubmed
    The Pidd (p53-induced protein with death domain) gene was shown to be induced by the tumour suppressor p53 and to mediate p53-dependent apoptosis in mouse and human cells, through interactions with components of both the mitochondrial and ..
  53. Baptiste Okoh N, Barsotti A, Prives C. A role for caspase 2 and PIDD in the process of p53-mediated apoptosis. Proc Natl Acad Sci U S A. 2008;105:1937-42 pubmed publisher
    ..transcriptional activation of numerous p53 target genes, it can induce expression of proapoptotic targets including PIDD and AIP1 at least to the same extent as wild-type p53...
  54. SHAPIRO R, Wasserman R, Bonagura V, Gupta S. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. J Clin Immunol. 2017;37:190-196 pubmed publisher
    An emerging paradigm for the treatment of primary immunodeficiency disease (PIDD) with immunoglobulin (IgG) replacement therapy emphasizes the tailoring of treatments to each patient with the goal of preventing infections and minimizing ..
  55. Oliver T, Meylan E, Chang G, Xue W, Burke J, Humpton T, et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell. 2011;43:57-71 pubmed publisher
    ..Caspase-2 is activated by the p53 target gene product PIDD (also known as LRDD) in a complex called the Caspase-2-PIDDosome...
  56. Wasserman R, Melamed I, Stein M, Engl W, Sharkhawy M, Leibl H, et al. Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency. J Clin Immunol. 2016;36:571-82 pubmed publisher
    Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, ..
  57. Thompson R, Shah R, Liu P, Gupta Y, Ando K, Aggarwal A, et al. An Inhibitor of PIDDosome Formation. Mol Cell. 2015;58:767-79 pubmed publisher
    The PIDDosome-PIDD-RAIDD-caspase-2 complex-is a proapoptotic caspase-activation platform of elusive significance...
  58. Piccini J, Sanders P, Shah R, Roberts G, Karst E, Turakhia M. Impact of Tachyarrhythmia Detection Rate and Time from Detection to Shock on Outcomes in Nationwide US Practice. Am J Cardiol. 2017;120:1325-1331 pubmed publisher
    ..detection: higher rate delayed detection (HRDD), higher rate early detection (HRED), lower rate delayed detection (LRDD), and lower rate early detection (LRED). Cox regression was used to compare mortality and shock-free survival...
  59. Oliver T, Mercer K, Sayles L, Burke J, Mendus D, Lovejoy K, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 2010;24:837-52 pubmed publisher
    ..levels of multiple DNA damage repair and cell cycle arrest-related genes, including p53-inducible protein with a death domain (Pidd). We demonstrate a novel role for PIDD as a regulator of chemotherapy response in human lung tumor cells.
  60. Jang T, Bae J, Park O, Kim J, Cho K, Jeon J, et al. Identification and analysis of dominant negative mutants of RAIDD and PIDD. Biochim Biophys Acta. 2010;1804:1557-63 pubmed publisher
    ..caspase-activating complex is the PIDDosome for caspase-2 activation, which is composed of 3 protein components, PIDD, RAIDD and Caspase-2...
  61. Tinel A, Eckert M, Logette E, Lippens S, Janssens S, Jaccard B, et al. Regulation of PIDD auto-proteolysis and activity by the molecular chaperone Hsp90. Cell Death Differ. 2011;18:506-15 pubmed publisher
    In response to DNA damage, p53-induced protein with a death domain (PIDD) forms a complex called the PIDDosome, which either consists of PIDD, RIP-associated protein with a death domain and caspase-2, forming a platform for the activation ..
  62. Huang L, Han D, Yang X, Qin B, Ji G, Yu L. PIDD4, a novel PIDD isoform without the LRR domain, can independently induce cell apoptosis in cytoplasm. Biochem Biophys Res Commun. 2011;407:86-91 pubmed publisher
    b>PIDD1 (P53-induced death domain) is a pro-apoptotic gene which can be induced by p53. So far, three alternative splicing products of human PIDD gene have been identified...
  63. Cuenin S, Tinel A, Janssens S, Tschopp J. p53-induced protein with a death domain (PIDD) isoforms differentially activate nuclear factor-kappaB and caspase-2 in response to genotoxic stress. Oncogene. 2008;27:387-96 pubmed
    ..Two isoforms of PIDD, PIDD (isoform 1) and LRDD (isoform 2), have already been reported and we describe here a third isoform...
  64. Mayor P, Eng K, Singel K, Abrams S, Odunsi K, Moysich K, et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018;141:1028-1035 pubmed publisher
    We evaluated the overall and site-specific incidence of cancer in subjects with primary immunodeficiency diseases (PIDD) enrolled in the United States Immune Deficiency Network (USIDNET) registry compared with age-adjusted cancer ..
  65. Vakifahmetoglu H, Olsson M, Orrenius S, Zhivotovsky B. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene. 2006;25:5683-92 pubmed
    ..Proposed mediators of caspase-2 activation include PIDDosome complex proteins PIDD and RAIDD...
  66. Jeong W, Rho J, Yoon Y, Yoo S, Jeong N, Ryu W, et al. Cytoplasmic and nuclear anti-apoptotic roles of ?B-crystallin in retinal pigment epithelial cells. PLoS ONE. 2012;7:e45754 pubmed publisher
    ..Taken together, these results suggest that ?B-crystallin prevents caspase activation by physically interacting with caspase subtypes in the cytoplasm and nucleus, thereby protecting RPE cells from MGO-induced apoptosis. ..
  67. Ando K, PARSONS M, Shah R, Charendoff C, Paris S, Liu P, et al. NPM1 directs PIDDosome-dependent caspase-2 activation in the nucleolus. J Cell Biol. 2017;216:1795-1810 pubmed publisher
    The PIDDosome (PIDD-RAIDD-caspase-2 complex) is considered to be the primary signaling platform for caspase-2 activation in response to genotoxic stress...
  68. Pick R, Badura S, Bösser S, Zörnig M. Upon intracellular processing, the C-terminal death domain-containing fragment of the p53-inducible PIDD/LRDD protein translocates to the nucleoli and interacts with nucleolin. Biochem Biophys Res Commun. 2006;349:1329-38 pubmed
    The p53-inducible and death domain-containing PIDD/LRDD protein has been described as an adaptor protein, which forms large protein complexes with RAIDD, another death domain-containing protein, leading to recruitment, and activation of ..
  69. Wasserman R, Ito D, Xiong Y, Ye X, Bonnet P, Li McLeod J. Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy. J Clin Immunol. 2017;37:180-186 pubmed publisher
    Patients with primary immunodeficiency diseases (PIDD) are at increased risk of infection and may require lifelong immunoglobulin G (IgG) replacement...
  70. Park H, Wu H. Crystallization and preliminary X-ray crystallographic studies of the oligomeric death-domain complex between PIDD and RAIDD. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63:229-32 pubmed
    ..The PIDDosome, which activates caspase-2, is composed of three protein components: PIDD, RAIDD and caspase-2...
  71. Ando K, Kernan J, Liu P, Sanda T, Logette E, Tschopp J, et al. PIDD death-domain phosphorylation by ATM controls prodeath versus prosurvival PIDDosome signaling. Mol Cell. 2012;47:681-93 pubmed publisher
    Biochemical evidence implicates the death-domain (DD) protein PIDD as a molecular switch capable of signaling cell survival or death in response to genotoxic stress...
  72. Berger M, Geng B, Cameron D, Murphy L, Schulman E. Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease. Respir Med. 2017;132:181-188 pubmed publisher
    More than half of all primary immune deficiency diseases (PIDD) affect antibody production and are well known as causes of recurrent sinusitis and lung infections...
  73. Heikaus S, Pejin I, Gabbert H, Ramp U, Mahotka C. PIDDosome expression and the role of caspase-2 activation for chemotherapy-induced apoptosis in RCCs. Cell Oncol. 2010;32:29-42 pubmed publisher
    ..of caspase-2, which can be alternatively spliced into caspase-2L and caspase-2S, and the other PIDDosome members PIDD and RAIDD in human tumours in vivo...
  74. Ballow M, Pinciaro P, Craig T, Kleiner G, Moy J, Ochs H, et al. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases. J Clin Immunol. 2016;36:583-9 pubmed publisher
    ..of Flebogamma® 5 % DIF for replacement therapy in children (age 2-16) with primary immunodeficiency diseases (PIDD)...